Risk of Cardiovascular Events Associated with Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population

Clinical Infectious Diseases

Volumn 61, Issue 3, 2015, Pages 445-452

  Desai, Manisha ^a,b   Joyce, Vilija ^c   Bendavid, Eran ^d,e   Olshen, Richard A ^b   Hlatky, Mark ^b   Chow, Adam ^c   Holodniy, Mark ^c   Barnett, Paul ^c   Owens, Douglas K ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d Center for Tobacco Policy Research   (United States)

^e Division of General Medical Disciplines   (United States)

Author keywords

antiretroviral therapy; cardiovascular event; HIV; myocardial infarction

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEPENDENT VARIABLE; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; UNITED STATES; VETERAN; VETERANS HEALTH; VIRUS LOAD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HIV INFECTIONS; LONGITUDINAL STUDY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; UNITED STATES; VETERANS;

EID: 84938579218     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ316     Document Type: Article

References (16)

1. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 2013; 8:e59551.
2. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26.
3. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
4. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-38.
5. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11:130-6.
6. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with abacavir use: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441-7.
7. Bedimo RJ,Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
8. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-98.
9. Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16:775-83.
10. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke 2002; 33:2465-70.
11. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005; 36:1776-81.
12. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiol 2000; 11:550-60.
13. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-64.
14. Sabin CA, Reiss P, Ryom L, et al; for the D:A:D study group. Is there continued evidence for an association between abacavir and myocardial infarction risk? [abstract 747LB] In: 21st Conference on Retroviruses and Opportunistic Infections, Boston, 2014.
15. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
16. Belloso WH, Orellana LC, Grinsztejn B, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010; 11:554-64.